Involvement of the constitutive complex formation of c-Ski/SnoN with Smads in the impaired negative feedback regulation of transforming growth factor β signaling in scleroderma fibroblasts

Arthritis and Rheumatism

Volumn 56, Issue 5, 2007, Pages 1694-1705

  Jinnin, Masatoshi ^a   Ihn, Hironobu ^b   Mimura, Yoshihiro ^a   Asano, Yoshihide ^a   Tamaki, Kunihiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; NEGATIVE FEEDBACK; NORTHERN BLOTTING; PATHOGENESIS; PLASMID; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCLERODERMA; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

ADULT; CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN TYPE I; DNA-BINDING PROTEINS; E1A-ASSOCIATED P300 PROTEIN; FEEDBACK, BIOCHEMICAL; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34248548638     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22588     Document Type: Article

References (46)

1. Korn JH. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1989;1:479-84.
2. Mauch C, Krieg T. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am 1990;16: 93-107.
3. Mauch C, Kozlowska E, Eckes B, Krieg T. Altered regulation of collagen metabolism in scleroderma fibroblasts grown within three-dimensional collagen gels. Exp Dermatol 1992;1:185-90.
4. Jelaska A, Arakawa M, Broketa G, Korn JH. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts: increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 1996;39:1338-46.
5. Wahl SM. Transforming growth factor β: the good, the bad, and the ugly. J Exp Med 1994;180:1587-90.
6. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004;113:253-64.
7. Massague J. Transforming growth factor-β family. Ann Rev Cell Biol 1990;6:597-641.
8. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy for determining the pathogenesis of systemic sclerosis: is transforming growth factor β the answer? Arthritis Rheum 1989;32:817-25.
9. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974;54:880-9.
10. Jimenez SA, Feldman G, Bashey RI, Bienkowski R, Rosenbloom J. Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis. Biochem J 1986; 237:837-43.
11. Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts. Biochem Biophys Res Commun 1992;187:45-50.
12. Hitraya EG, Jimenez SA. Transcriptional activation of the α1(I) procollagen gene in systemic sclerosis dermal fibroblasts: role of intronic sequences. Arthritis Rheum 1996;39:1347-54.
13. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
14. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001;44:474-80.
15. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-β responses. Cell 1998;95:737-40.
16. Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor β signaling. Proc Natl Acad Sci U S A 1999;96:12442-7.
17. Wotton D, Lo RS, Lee S, Massague J. A Smad transcriptional corepressor. Cell 1999;97:29-39.
18. Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-β-induced transcriptional activation. Genes Dev 1998;12:2153-63.
19. Janknecht R, Wells NJ, Hunter T. TGF-β-stimulated cooperation of Smad proteins with the coactivators CBP/p300. Genes Dev 1998;12:2114-9.
20. Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K, et al. c-Ski acts as a transcriptional co-repressor in transforming growth factor-β signaling through interaction with Smads. J Biol Chem 1999;274:35269-77.
21. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein. Science 1999;286:771-4.
22. Yang J, Zhang X, Li Y, Liu Y. Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: an amplification mechanism for TGF-β1 signaling. J Am Soc Nephrol 2003;14:3167-77.
23. Ihn H, Ohnishi K, Tamaki T, LeRoy EC, Trojanowska M. Transcriptional regulation of the human α2(I) collagen gene: combined action of upstream stimulatory and inhibitory cis-acting elements. J Biol Chem 1996;271:26717-23.
24. Ihn H, LeRoy EC, Trojanowska M. Oncostatin M stimulates transcription of the human α2(I) collagen gene via the Sp1/Sp3-binding site. J Biol Chem 1997;272:24666-72.
25. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001;276: 10594-601.
26. Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001;44:731-4.
27. Ihn H, Tamaki K. Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene. Arthritis Rheum 2000;43: 2240-7.
28. Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K, et al. c-myc is a downstream target of the Smad pathway. J Biol Chem 2002;277:854-61.
29. Ihn H, Yamane K, Asano Y, Kubo M, Tamaki K. IL-4 upregulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase dependent pathway. J Immunol 2002;168:1895-902.
30. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Phosphatidylinositol 3-kinase is involved in α2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol 2004;172:7123-35.
31. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, et al. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signalling. Nature 1997;389:631-5.
32. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 1997;89:1165-73.
33. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol Cell 2000; 6:1365-75.
34. Liu X, Sun Y, Weinberg RA, Lodish HF. Ski/Sno and TGF-β signaling. Cytokine Growth Factor Rev 2001;12:1-8.
35. Nomura N, Sasamoto S, Ishii S, Date T, Matsui M, Ishizaki R. Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res 1989;17:5489-500.
36. He J, Tegen SB, Krawitz AR, Martin GS, Luo K. The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins. J Biol Chem 2003;278:30540-7.
37. Pearson-White S, Crittenden R. Proto-oncogene Sno expression, alternative isoforms and immediate early serum response. Nucleic Acids Res 1997;25:2930-7.
38. Li Y, Turck CM, Teumer JK, Stavnezer E. Unique sequence, ski, in Sloan-Kettering avian retroviruses with properties of a new cell-derived oncogene. J Virol 1986;57:1065-72.
39. Zheng G, Teumer J, Colmenares C, Richmond C, Stavnezer E. Identification of a core functional and structural domain of the v-Ski oncoprotein responsible for both transformation and myogenesis. Oncogene 1997;15:459-71.
40. Reed JA, Bales E, Xu W, Okan NA, Bandyopadhyay D, Medrano EE. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo. Cancer Res 2001;61:8074-8.
41. Luo K. Ski and SnoN: negative regulators of TGF-β signaling. Curr Opin Genet Dev 2004;14:65-70.
42. Prunier C, Pessah M, Ferrand N, Seo SR, Howe P, Atfi A. The oncoprotein Ski acts as an antagonist of transforming growth factor-β signaling by suppressing Smad2 phosphorylation. J Biol Chem 2003;278:26249-57.
43. Nagase T, Mizuguchi G, Nomura N, Ishizaki R, Ueno Y, Ishii S. Requirement of protein co-factor for the DNA-binding function of the human ski proto-oncogene product. Nucleic Acids Res 1990; 18:337-43.
44. Rappolee DA, Brenner CA, Schultz R, Mark D, Werb Z. Developmental expression of PDGF, TGF-α, and TGF-β genes in preimplantation mouse embryos. Science 1988;241:1823-5.
45. De Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 2000;92: 1388-402.
46. Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford) 2006;45:157-65.